2023
Vagus Nerve Stimulation Rescues Persistent Pain Following Orthopedic Surgery In Adult Mice
Wu P, De Caceres A, Baht G, Terrando N, Jordt S. Vagus Nerve Stimulation Rescues Persistent Pain Following Orthopedic Surgery In Adult Mice. Journal Of Pain 2023, 24: 10. DOI: 10.1016/j.jpain.2023.02.044.Peer-Reviewed Original ResearchVagus nerve stimulationPostoperative painOrthopedic surgeryNerve stimulationPain 2 yearsAnti-nociceptive effectsPersistent postoperative painSatellite glial cellsAnti-inflammatory effectsMajor clinical problemBilateral hindTibial surgeryMicroglia activationRisk patientsPain sensitizationPersistent painVagus nervePain behaviorEffective therapyFemale miceSpinal cordWeekly treatmentGlial cellsGFAP expressionInvasive procedures
2009
Lupus immunotherapy using CD4 targeted nanoparticles (48.29)
Look M, Stern E, Wang Q, DiPlacido L, Craft J, Fahmy T. Lupus immunotherapy using CD4 targeted nanoparticles (48.29). The Journal Of Immunology 2009, 182: 48.29-48.29. DOI: 10.4049/jimmunol.182.supp.48.29.Peer-Reviewed Original ResearchNZB/W F1 miceW F1 miceCD4 T cellsImmunosuppressive drugsDisease progressionF1 miceT cellsImmunosuppressive drug dosageSystemic lupus erythematosusNanoparticle therapyConventional therapeutic regimensFrequency of dosageLupus erythematosusAutoantibody productionTherapeutic regimensWeekly treatmentTherapeutic featuresAnimal modelsB cellsDrug dosageTherapeutic efficacyLupusImmunotherapyTherapyMice
2002
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer. Journal Of Clinical Oncology 2002, 20: 1800-1808. PMID: 11919237, DOI: 10.1200/jco.2002.07.058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDisease ProgressionDocetaxelDrug Administration ScheduleFemaleGene Expression Regulation, NeoplasticHumansIn Situ Hybridization, FluorescenceMiddle AgedPaclitaxelReceptor, ErbB-2TaxoidsTime FactorsTrastuzumabTreatment OutcomeUp-RegulationConceptsMetastatic breast cancerOverall response rateWeekly docetaxelBreast cancerPhase II studySecond-line therapyTrastuzumab-based therapyWeek of restExtracellular domain levelsII studyLoading doseMedian timeExcessive tearingFluid retentionECD concentrationsRepetitive dosingWeekly treatmentECD levelsPatientsTrastuzumabActive combinationResponse rateDocetaxelCancerAcute toxicity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply